Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Desmoid Tumor Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CTNNB1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CTNNB1 Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Ideal for PPI and PROTAC assays. |
View CTNNB1 Products |
| Gene Delivery | CTNNB1 Promise-ORF / Lentivirus Full-length ORF for stable reporter cell lines. |
View CTNNB1 Products |
| Benchmark Ab | Anti-CTNNB1 (Sequence-verified Benchmark) Recombinant positive control for western blot and target engagement. |
View CTNNB1 Products |
| Validator | CTNNB1 siRNA Set For knockdown verification in cell-based assays. |
View CTNNB1 Products |
| Related Target A | TCF4 Key downstream transcription factor partner for PPI disruption screening. |
View TCF4 Products |
| Related Target B | GSK3B Upstream kinase governing CTNNB1 degradation complex. |
View GSK3B Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Targeting Drug-Resistant/Oncogenic Mutants (e.g., S45F, T41A) | Comprehensive Mutant Panel available with Sequence Verified accuracy and >95% purity. |
| PROTAC Ternary Complex Validation | High-purity soluble proteins preserving native conformation for precise SPR/AlphaLISA kinetics. |
| Lack of Reliable Pathway Controls | Recombinant Benchmark Antibodies included for reproducible target engagement confirmation. |
| Off-Target Phenotypic False Positives | Validated siRNA included for rigorous biological specificity checks. |
Live CTNNB1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CTNNB1 (Beta Catenin) therapeutics is intensifying, with major players shifting focus from traditional small molecule inhibitors to Targeted Protein Degradation (PROTACs and molecular glues). As an intracellular transcription co-activator historically deemed "undruggable" due to its large, flat protein-protein interaction (PPI) surfaces, CTNNB1 is experiencing a renaissance in drug development. As first-generation therapies reach the clinic for indications like desmoid tumors and colorectal cancer, the next wave of R&D is targeting mutant-specific degradation to overcome immune evasion and Wnt-pathway-driven tumor stemness.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Kymera Therapeutics, Foghorn | Colorectal Cancer, Solid Tumors | Ternary Complex Assay (Need high-purity WT & Mutant Proteins) |
| PPI Inhibitor (Small Mol) | Prism BioLab, Iterion | Desmoid Tumors, HCC | PPI Disruption Assay (Need CTNNB1 & TCF4 binding pairs) |
| RNAi / ASO | Dicerna (Novo Nordisk) | Hepatocellular Carcinoma | Transcriptional Silencing (Need validated siRNA/reporter lines) |
| Peptide Therapeutics | Academic Spin-offs | Wnt-driven malignancies | Affinity Kinetics (Need Endotoxin-controlled Antigens) |